Vistagen reports positive Phase 3 PALISADE-2 fasedienol results for SAD; Q1 net loss $6.9M

Vistagen Therapeutics, Inc.

2025-Q1 EPS reported -$0.94 revenue$177,000

Phase 3 PALISADE-2: fasedienol met primary endpoint (SUDS LS mean diff -5.8, p=0.015) and secondary CGI-I responder rate (37.7% vs 21.4%, p=0.033).
Net loss for Q1 FY2024 was $6.9M, down from $19.8M YoY; R&D expense decreased $11.1M to $4.2M.
Cash $9.6M at June 30, 2023; raised ~$16.9M from shares in July/Aug 2023, with additional $15.2M expected by Aug 14.
Itruvone (PH10) moving to Phase 2B for MDD after successful US Phase 1; PH80 Phase 2A showed significant hot flash reduction (p<.001).
Planning Phase 3 PALISADE-3 and FEARLESS in 2024; fasedienol well-tolerated with no serious AEs.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Vistagen Therapeutics, Inc. reported financial results for fiscal year 2024 first quarter ended June 30, 2023.

Period: fiscal year 2024 first quarter ended June 30, 2023
Result: reported results

Exact text from the filing

On August 10, 2023, Vistagen Therapeutics, Inc. (the “ Company ”) issued a press release to announce the Company’s financial results for its fiscal year 2024 first quarter ended June 30, 2023.

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

Vistagen Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-23-023114

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.